These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 15626583)

  • 1. Inefficient central nervous system delivery limits the use of ibuprofen in neurodegenerative diseases.
    Mannila A; Rautio J; Lehtonen M; Järvinen T; Savolainen J
    Eur J Pharm Sci; 2005 Jan; 24(1):101-5. PubMed ID: 15626583
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Challenges and opportunities in CNS delivery of therapeutics for neurodegenerative diseases.
    Barchet TM; Amiji MM
    Expert Opin Drug Deliv; 2009 Mar; 6(3):211-25. PubMed ID: 19290842
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ubiquitin proteasome system as a pharmacological target in neurodegeneration.
    Hol EM; Fischer DF; Ovaa H; Scheper W
    Expert Rev Neurother; 2006 Sep; 6(9):1337-47. PubMed ID: 17009921
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Poly(n-butylcyanoacrylate) nanoparticles coated with polysorbate 80 for the targeted delivery of rivastigmine into the brain to treat Alzheimer's disease.
    Wilson B; Samanta MK; Santhi K; Kumar KP; Paramakrishnan N; Suresh B
    Brain Res; 2008 Mar; 1200():159-68. PubMed ID: 18291351
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis, in vitro and in vivo characterization of glycosyl derivatives of ibuprofen as novel prodrugs for brain drug delivery.
    Chen Q; Gong T; Liu J; Wang X; Fu H; Zhang Z
    J Drug Target; 2009 May; 17(4):318-28. PubMed ID: 19558357
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual-targeting for brain-specific drug delivery: synthesis and biological evaluation.
    Yue Q; Peng Y; Zhao Y; Lu R; Fu Q; Chen Y; Yang Y; Hai L; Guo L; Wu Y
    Drug Deliv; 2018 Nov; 25(1):426-434. PubMed ID: 29382239
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic potential of controlled drug delivery systems in neurodegenerative diseases.
    Popovic N; Brundin P
    Int J Pharm; 2006 May; 314(2):120-6. PubMed ID: 16529886
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chronic ibuprofen administration worsens cognitive outcome following traumatic brain injury in rats.
    Browne KD; Iwata A; Putt ME; Smith DH
    Exp Neurol; 2006 Oct; 201(2):301-7. PubMed ID: 16764859
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potential prodrugs of non-steroidal anti-inflammatory agents for targeted drug delivery to the CNS.
    Perioli L; Ambrogi V; Bernardini C; Grandolini G; Ricci M; Giovagnoli S; Rossi C
    Eur J Med Chem; 2004 Aug; 39(8):715-27. PubMed ID: 15276305
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multi-functional drugs for various CNS targets in the treatment of neurodegenerative disorders.
    Youdim MB; Buccafusco JJ
    Trends Pharmacol Sci; 2005 Jan; 26(1):27-35. PubMed ID: 15629202
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemokine receptors in the central nervous system: role in brain inflammation and neurodegenerative diseases.
    Cartier L; Hartley O; Dubois-Dauphin M; Krause KH
    Brain Res Brain Res Rev; 2005 Feb; 48(1):16-42. PubMed ID: 15708626
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhancement of antinociception by co-administration of ibuprofen and caffeine in arthritic rats.
    López JR; Domínguez-Ramírez AM; Cook HJ; Bravo G; Díaz-Reval MI; Déciga-Campos M; López-Muñoz FJ
    Eur J Pharmacol; 2006 Aug; 544(1-3):31-8. PubMed ID: 16872598
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cerebrospinal fluid distribution of ibuprofen after intravenous administration in children.
    Kokki H; Kumpulainen E; Lehtonen M; Laisalmi M; Heikkinen M; Savolainen J; Rautio J
    Pediatrics; 2007 Oct; 120(4):e1002-8. PubMed ID: 17908721
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elevated manganese levels in blood and CNS in human prion disease.
    Hesketh S; Sassoon J; Knight R; Brown DR
    Mol Cell Neurosci; 2008 Mar; 37(3):590-8. PubMed ID: 18234506
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of alpha-synuclein in neurodegenerative diseases: a potential target for new treatment strategies?
    Windisch M; Wolf H; Hutter-Paier B; Wronski R
    Neurodegener Dis; 2008; 5(3-4):218-21. PubMed ID: 18322395
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Distribution of the novel antifolate pemetrexed to the brain.
    Dai H; Chen Y; Elmquist WF
    J Pharmacol Exp Ther; 2005 Oct; 315(1):222-9. PubMed ID: 15987831
    [TBL] [Abstract][Full Text] [Related]  

  • 17. To be or not to be (inflamed)--is that the question in anti-inflammatory drug therapy of neurodegenerative disorders?
    Marchetti B; Abbracchio MP
    Trends Pharmacol Sci; 2005 Oct; 26(10):517-25. PubMed ID: 16126283
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Central nervous system distribution kinetics of indinavir in rats.
    Hamidi M
    J Pharm Pharmacol; 2007 Aug; 59(8):1077-85. PubMed ID: 17725849
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nanotechnological applications for the treatment of neurodegenerative disorders.
    Modi G; Pillay V; Choonara YE; Ndesendo VM; du Toit LC; Naidoo D
    Prog Neurobiol; 2009 Aug; 88(4):272-85. PubMed ID: 19486920
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oxidative stress, mitochondrial dysfunction and cellular stress response in Friedreich's ataxia.
    Calabrese V; Lodi R; Tonon C; D'Agata V; Sapienza M; Scapagnini G; Mangiameli A; Pennisi G; Stella AM; Butterfield DA
    J Neurol Sci; 2005 Jun; 233(1-2):145-62. PubMed ID: 15896810
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.